SPDR S&P Biotech ETF Newsroom

Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps

Benzinga12:17 ET

$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today

Benzinga12:00 ET

Natera Analyst Ratings

BenzingaSep 13 11:26 ET · Ratings

Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug

Seeking AlphaSep 13 11:20 ET

Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences

BenzingaSep 13 07:06 ET

US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.

① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.

cls.cnSep 12 18:22 ET

Gilead Sciences Goes Ex-dividend Tomorrow

Seeking AlphaSep 12 14:45 ET

Cracking The Code: Understanding Analyst Reviews For Exact Sciences

BenzingaSep 12 14:00 ET

What the Options Market Tells Us About Gilead Sciences

BenzingaSep 12 11:02 ET

Gilead Posts Second Late-stage Win for Twice-yearly HIV Therapy

Seeking AlphaSep 12 09:05 ET

Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.

BenzingaSep 12 08:38 ET

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

BenzingaSep 12 08:21 ET

Exact Sciences Analyst Ratings

BenzingaSep 12 06:40 ET · Ratings

Sanofi Reports Positive Phase 3 Results for Dupixent for CSU

Seeking AlphaSep 11 17:05 ET

UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars

BenzingaSep 11 14:59 ET

Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan

BenzingaSep 11 13:55 ET

Exact Sciences Spikes Ahead of Data for Blood-based Cancer Test

Seeking AlphaSep 11 13:31 ET

What the Options Market Tells Us About AbbVie

BenzingaSep 11 13:31 ET

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years

BenzingaSep 11 13:30 ET

Viking Therapeutics Unusual Options Activity For September 11

BenzingaSep 11 12:30 ET